John J. Chandler
Corporate Officer/Principal bei Licensing Executives Society
Profil
John J.
Chandler has been a Director of Apex Bioventures Acquisition Corp.
since June 1, 2006.
Mr. Chandler has over 35 years of business development and mergers and acquisitions experience in the pharmaceutical, biotech, specialty pharmaceutical, medical device and chemical industries.
From May 1998 to September 2006, he was Vice President-Corporate Development for Cellegy Pharmaceuticals, Inc. From January 1995 to May 1998, Mr. Chandler was Vice President-Europe for the Sherwood-Davis & Geck.
From August 1968 to December 1994, he worked at American Cyanamid Company, beginning as a Sales Representative and held various senior management positions, including Vice President of Lederle International.
Mr. Chandler is a member of the Licensing Executives Society.
He received an MBA in Marketing from Seton Hall University and a BS in Biology from Queens College of the City University of New York.
Aktive Positionen von John J. Chandler
| Unternehmen | Position | Beginn |
|---|---|---|
| Licensing Executives Society | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von John J. Chandler
| Unternehmen | Position | Ende |
|---|---|---|
Apex Bioventures Acquisition Corp.
 Apex Bioventures Acquisition Corp. Financial ConglomeratesFinance The Company is a blank check company. It is formed to acquire one or more domestic or foreign operating business in the healthcare industry through merger, capital stock exchange, asset acquisition or other similar business combination. The Company is in the development stage. On February 5, 2008, the Company entered into an Agreement and Plan of Merger with Dynogen Pharmaceuticals, Inc and its acting representatives. | Direktor/Vorstandsmitglied | 04.06.2009 |
Cellegy Pharmaceuticals, Inc.
 Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Corporate Officer/Principal | 01.09.2006 |
| Sherwood Davis & Geck | Corporate Officer/Principal | 01.05.1998 |
| Cyanamid International Corp. | Corporate Officer/Principal | 01.12.1994 |
| Lederle International | Corporate Officer/Principal | - |
Ausbildung von John J. Chandler
| City University of New York | Undergraduate Degree |
| Seton Hall University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Cellegy Pharmaceuticals, Inc.
Cellegy Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cellegy Pharmaceuticals specialty biopharmaceutical company, that is primarily engaged in the development and commercialization of prescription drugs targeting women’s health care, including reduction in transmission of HIV and female sexual dysfunction, and gastrointestinal conditions using proprietary topical formulations and nitric oxide, or NO, donor technologies | Health Technology |
Apex Bioventures Acquisition Corp.
Apex Bioventures Acquisition Corp. Financial ConglomeratesFinance The Company is a blank check company. It is formed to acquire one or more domestic or foreign operating business in the healthcare industry through merger, capital stock exchange, asset acquisition or other similar business combination. The Company is in the development stage. On February 5, 2008, the Company entered into an Agreement and Plan of Merger with Dynogen Pharmaceuticals, Inc and its acting representatives. | Finance |
| Sherwood Davis & Geck | Health Technology |
| Licensing Executives Society | |
| Cyanamid International Corp. | |
| Lederle International |
